Committee expresses concern about availability of albuterol HFA supply on chlorofluorocarbon phase-out date. Schering-Plough and GSK tell FDA it will take up to 18 months to expand annual production capacity to 30 mil. doses each.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
